Percutaneous laser ablation: a new contribution to unresectable high-risk metastatic retroperitoneal lesions?

Related Articles

Percutaneous laser ablation: a new contribution to unresectable high-risk metastatic retroperitoneal lesions?

Oncotarget. 2016 Dec 10;:

Authors: Jiang T, Deng Z, Tian G, Chen F, Bao H, Li J, Wang W

Abstract
BACKGROUND & AIMS: Metastasis in retroperitoneal lymph nodes is one of the signs of advanced stage or terminal stage of malignancy. We performed a trial to assess the safety and efficacy of ultrasonography (US)-guided local neodymium-doped yttrium aluminum garnet (Nd:YAG) laser ablation for metastatic lymph nodes in the retroperitoneal region.
METHODS: We evaluated 4 cases of retroperitoneal metastatic lymph nodes treated using US-guided Nd:YAG laser ablation. Additionally, we reviewed the PubMed database for articles on thermal ablation of retroperitoneal lesions until March 2016, without language limitations.
RESULTS: In our study, all lesions were nearly completely ablated with mild discomfort, including pain and fever at the 3-month follow-up. In the literature review, a total of 398 patients with 491 retroperitoneal tumors were identified, and complications after the procedure included enterovesical fistula, fecal incontinence, and hematoma.
CONCLUSIONS: Percutaneous laser ablation could be a theoretically promising approach for retroperitoneal metastatic lesions. ClinicalTrials.gov number: NCT02822053.

PMID: 27974691 [PubMed - as supplied by publisher]

http://ift.tt/2gRsVHN